Coumermycin A1
Based on 31 publication(s) in Google Scholar
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.14%
- No. CAS: 4434-05-3
- Fòrmula: C55H59N5O20
- Peso molecular:1110.08
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-B0425A
Novobiocin sodiumAntibiotic/Hsp90 Inhibitor -
HY-14654
AspirinCOX Inhibitor -
HY-10219
RapamycinmTOR Inhibitor -
HY-12000
AG490EGFR Inhibitor -
HY-16106
TalazoparibPARP Inhibitor -
HY-13259
MG-132Proteasome Inhibitor -
HY-15205
GanetespibHSP90 Inhibitor -
HY-13780
Vinblastine sulfatenAChR Inhibitor -
HY-10971
AlisertibAurora A Kinase Inhibitor -
HY-P1061
ColivelinNeuroprotectant/STAT3 Activator -
HY-112665
Virginiamycin ComplexAntibiotic
Publications Citing Use of MedChemExpress (MCE) Coumermycin A1
More- J Nanobiotechnology. 2025 Oct 10;23(1):649. [Abstract]
- Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
- Phytomedicine. 2025 Nov 25:148:157414. [Abstract]
- Phytomedicine. 2025 Oct:146:157099. [Abstract]
- Phytother Res. 2025 Sep 27. [Abstract]
- Clin Transl Med. 2026 Feb;16(2):e70607. [Abstract]
- Eur J Pharmacol. 2023 Sep 5:954:175876. [Abstract]
- Int Immunopharmacol. 2026 Nov 1:188:117305.
- Int Immunopharmacol. 2024 Oct 18;143(Pt 2):113416. [Abstract]
- Int Immunopharmacol. 2022 Oct:111:109107. [Abstract]
- Inflammation. 2024 Feb;47(1):209-226. [Abstract]
- Sci Rep. 2025 Nov 28;15(1):42738. [Abstract]
- Brain Res Bull. 2026 Apr:237:111785. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2026 Feb;1873(2):120094. [Abstract]
- Metab Brain Dis. 2025 Oct 30;40(8):301. [Abstract]
- Metab Brain Dis. 2025 Oct 14;40(7):289. [Abstract]
- World J Clin Oncol. 2025 Dec 24;16(12):112626. [Abstract]
- Int Immunol. 2026 Mar 16:dxag014. [Abstract]
- Mol Biol Rep. 2024 Jan 22;51(1):176. [Abstract]
- Immunopharmacol Immunotoxicol. 2024 Oct;46(5):672-684. [Abstract]
- Tissue Cell. 2023 Aug:83:102145. [Abstract]
- Cell Biochem Biophys. 2025 Jun;83(2):1785-1798. [Abstract]
- BMC Immunol. 2025 Jul 30;26(1):57. [Abstract]
- Biomol Biomed. 2024 Dec 11;25(1):249-258. [Abstract]
- Gene. 2026 Mar 15:983:149991. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Jun 1:1259:124600. [Abstract]
- J Stroke Cerebrovasc Dis. 2025 Jan;34(1):108114. [Abstract]
- Journal of Traditional Chinese Medical Sciences. 2026 Sep 20.
- SSRN. 2026 Jun 9.
- SSRN. 2025 Mar 19.
- Research Square Print. 2022 Aug.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
WB
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
2 μM
Compound: Coumermycin A1
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 30048133] |
| SK-BR-3 | IC50 |
2 μM
Compound: Coumermycin A1
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 30048133] |
In Vitro
Chemical Information
-
No. CAS 4434-05-3
-
Appearance Solid
-
Peso molecular 1110.08
-
Fòrmula C55H59N5O20
-
Color White to off-white
-
SMILES
OC(C1=CC=C(O[C@@H]([C@H](O)[C@H](OC(C2=CC=C(C)N2)=O)[C@H]3OC)OC3(C)C)C(C)=C1O4)=C(NC(C5=CNC(C(NC6=C(O)C7=CC=C(O[C@@H]([C@H](O)[C@H](OC(C8=CC=C(C)N8)=O)[C@H]9OC)OC9(C)C)C(C)=C7OC6=O)=O)=C5C)=O)C4=O
-
Structure Classification
-
Initial Source
Streptomyces rishiriensis.
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (31)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
Targeting JAK2 with a multifunctional nanoinhibitor for long-lasting anti-inflammatory effects and bone repair. [Abstract]2025 Oct 10;23(1):649. PMID: 41074120 -
Cell Rep Med
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]2024 Jun 18;5(6):101592. PMID: 38843841
Coumermycin A1 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
MYD88-GyrB or MYD88 mutant-GyrB MV4-11 cells stimulated with different reagents (Coumermycin A, 1 ng/mL; SSO, 50 μM) for 3 days were further used for T cell proliferation assay.
-
Phytomedicine
Baicalin ameliorates dextran sulfate solidum-induced colitis by modulating Th17-macrophage immune network via JAK2/STAT3/IL-17/NF-κB pathway. [Abstract]2025 Nov 25:148:157414. PMID: 41124707 -
Phytomedicine
2025 Oct:146:157099. PMID: 40774011 -
Phytother Res
Hesperidin Inhibits Oxidative Stress and Apoptosis of Granulosa Cells in Polycystic Ovarian Syndrome Through the JAK2/STAT3 and PI3K/AKT Pathways. [Abstract]2025 Sep 27. PMID: 41014201 -
Clin Transl Med
Adipocyte fatty acid-binding protein as a cerebrospinal fluid-accessible biomarker and druggable target in subarachnoid haemorrhage: Linking fatty acid dysregulation to microglial neuroinflammation. [Abstract]2026 Feb;16(2):e70607. PMID: 41612866 -
Eur J Pharmacol
Eriocalyxin B ameliorated Crohn's disease-like colitis by restricting M1 macrophage polarization through JAK2/STAT1 signalling. [Abstract]2023 Sep 5:954:175876. PMID: 37391008
Coumermycin A1 purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Sep 5:954:175876. [Abstract]
MLE-12 cells were inoculated in 6-well plates and grown to 60% confluence. The cells were incubated with Coumermycin A1, JAK-IN-21, Colivelin TFA, and Stattic in culture medium for 48 h. The medium was then refreshed, followed by a 24-h pretreatment with EGCG, and finally exposure to LPS for 10 h. Protein levels of JAK2, p-JAK2, STAT3, and p-STAT3 were measured by western blotting.
-
-
Int Immunopharmacol
NLRP3 regulates ferroptosis via the JAK2/STAT3 pathway in asthma inflammation: Insights from in vivo and in vitro studies. [Abstract]2024 Oct 18;143(Pt 2):113416. PMID: 39426227 -
Int Immunopharmacol
Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition contributes to the alleviation of oxidative injury and collagen synthesis during pulmonary fibrosis. [Abstract]2022 Oct:111:109107. PMID: 35932616 -
Inflammation
Fibroblast Growth Factor 21 Relieves Lipopolysaccharide-Induced Acute Lung Injury by Suppressing JAK2/STAT3 Signaling Pathway. [Abstract]2024 Feb;47(1):209-226. PMID: 37864659
Coumermycin A1 purchased from MedChemExpress. Usage Cited in: Inflammation. 2024 Feb;47(1):209-226. [Abstract]
The wet/dry ratio, cell counts and protein levels in BALF of lung tissue in LPS + FGF21 group were alleviated compared with LPS group, while the therapeutic effect of FGF21 was reversed by Coumermycin A1.
Coumermycin A1 purchased from MedChemExpress. Usage Cited in: Inflammation. 2024 Feb;47(1):209-226. [Abstract]
Representative H&E staining image of the lung tissue of control group, LPS group, LPS + FGF21 group, and LPS + FGF21 + Coumermycin A1 group (n = 10), scale bar = 50 μm.
Coumermycin A1 purchased from MedChemExpress. Usage Cited in: Inflammation. 2024 Feb;47(1):209-226. [Abstract]
The lung injury score of control group, LPS group, LPS + FGF21 group, and LPS + FGF21 + Coumermycin A1 group was evaluated.
-
Sci Rep
Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced inflammation via the 67LR/JAK2/STAT3 signaling pathway. [Abstract]2025 Nov 28;15(1):42738. PMID: 41315587 -
Brain Res Bull
MiR-135b-5p relieves sevoflurane-induced postoperative cognitive dysfunction by inhibiting JAK2-STAT3-mediated hepcidin upregulation. [Abstract]2026 Apr:237:111785. PMID: 41720353 -
Biochim Biophys Acta Mol Cell Res
Activation of YBX1 and JAK2/STAT3 pathways by RIOK1 increases lenvatinib resistance in hepatocellular carcinoma cells. [Abstract]2026 Feb;1873(2):120094. PMID: 41354180 -
Metab Brain Dis
β-Caryophyllene modulates the JAK2/STAT3 signaling pathway to downregulate neutrophil extracellular traps and alleviate cerebral ischemia-reperfusion injury. [Abstract]2025 Oct 30;40(8):301. PMID: 41165931 -
Metab Brain Dis
SOCS2 alleviates traumatic brain injury-induced mitochondrial damage and parthanatos in endothelial cells by inhibiting the JAK2/STAT3 signaling pathway. [Abstract]2025 Oct 14;40(7):289. PMID: 41085788 -
World J Clin Oncol
Yin Yang 1 activates JAK-STAT3-mediated epithelial-mesenchymal transition in Helicobacter pylori-induced gastric cancer progression. [Abstract]2025 Dec 24;16(12):112626. PMID: 41480166 -
Int Immunol
ELAVL1 modulates periodontal ligament fibroblast pyroptosis in periodontitis through the JAK2/STAT3/NLRP3 axis. [Abstract]2026 Mar 16:dxag014. PMID: 41838803 -
Mol Biol Rep
Corosolic acid enhances oxidative stress-induced apoptosis and senescence in pancreatic cancer cells by inhibiting the JAK2/STAT3 pathway. [Abstract]2024 Jan 22;51(1):176. PMID: 38252208 -
Immunopharmacol Immunotoxicol
Sunitinib alleviates hepatic ischemia reperfusion injury by inhibiting the JAK2/STAT pathway and promoting the M2 polarization of macrophages. [Abstract]2024 Oct;46(5):672-684. PMID: 39155607 -
Tissue Cell
Liuwei Anxiao San protects gastric mucosa from gastric ulcer in rats by regulating the JAK2/STAT3 pathway. [Abstract]2023 Aug:83:102145. PMID: 37437331 -
Cell Biochem Biophys
Sirt4 Overexpression Modulates the JAK2/STAT3 and PI3K/AKT/mTOR Axes to Alleviate Sepsis-Induced Acute Lung Injury. [Abstract]2025 Jun;83(2):1785-1798. PMID: 39400781 -
BMC Immunol
Titanium implant can promote M2 polarization with macrophages activation which contribute to osteogenesis and angiogenesis via inactivates JAKS signaling pathway. [Abstract]2025 Jul 30;26(1):57. PMID: 40739176 -
Biomol Biomed
Botulinum toxin type A inhibits the formation of hypertrophic scar through the JAK2/STAT3 pathway. [Abstract]2024 Dec 11;25(1):249-258. PMID: 39132968 -
Gene
Revealing the dual mechanisms of Wuwei Wentong Chubi Capsule in alleviating rheumatoid arthritis: synergistic anti-inflammatory and anti-coagulant effects. [Abstract]2026 Mar 15:983:149991. PMID: 41482061 -
J Chromatogr B Analyt Technol Biomed Life Sci
Integrating 16srRNA sequencing, non-targeted metabolomics, and transcriptome sequencing to explore the mechanism of Total glucosides of paeony alleviating ulcerative colitis. [Abstract]2025 Jun 1:1259:124600. PMID: 40286482 -
J Stroke Cerebrovasc Dis
Loganin attenuates the inflammation, oxidative stress, and apoptosis through the JAK2/STAT3 pathway in cerebral ischemia-reperfusion injury. [Abstract]2025 Jan;34(1):108114. PMID: 39537043 -
-
-
-
Solvente y solubilidad
In Vitro:
DMSO : 10 mg/mL (9.01 mM; ultrasonic and warming and adjust pH to 2 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9008 mL | 4.5042 mL | 9.0084 mL | 22.5209 mL |
| 5 mM | 0.1802 mL | 0.9008 mL | 1.8017 mL | 4.5042 mL |
Coumermycin A1 Related Classifications
HY-N7452 Related Classifications
Powered by Bioz